Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$1100.05

Earnings Summary

Revenue
$3145Mn
Net Profits
$722Mn
Net Profit Margins
22.96%
PE Ratio
31.64

Highlights

Revenue:

Regeneron Pharmaceuticals, Inc.’s revenue fell -0.54% since last year same period to $3145Mn in the Q1 2024. On a quarterly growth basis, Regeneron Pharmaceuticals, Inc. has generated -8.42% fall in its revenue since last 3-months.

Net Profits:

Regeneron Pharmaceuticals, Inc.’s net profit fell -11.71% since last year same period to $722Mn in the Q1 2024. On a quarterly growth basis, Regeneron Pharmaceuticals, Inc. has generated -37.74% fall in its net profits since last 3-months.

Net Profit Margins:

Regeneron Pharmaceuticals, Inc.’s net profit margin fell -11.23% since last year same period to 22.96% in the Q1 2024. On a quarterly growth basis, Regeneron Pharmaceuticals, Inc. has generated -32.01% fall in its net profit margins since last 3-months.

PE Ratio:

Regeneron Pharmaceuticals, Inc.’s price-to-earnings ratio after this Q1 2024 earnings stands at 31.64.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Regeneron Pharmaceuticals, Inc. post its latest quarter earnings

EPS Estimate Current Quarter
10.59
EPS Estimate Current Year
10.59

Highlights

EPS Estimate Current Quarter:

Regeneron Pharmaceuticals, Inc.’s earning per share (EPS) estimates for the current quarter stand at 10.59 - a 4.96% jump from last quarter’s estimates.

EPS Estimate Current Year:

Regeneron Pharmaceuticals, Inc.’s earning per share (EPS) estimates for the current year stand at 10.59.

Key Ratios

Key ratios of the Regeneron Pharmaceuticals, Inc. post its Q1 2024 earnings

Earning Per Share (EPS)
9.55
Return on Assets (ROA)
0.08
Return on Equity (ROE)
0.15

Highlights

Earning Per Share (EPS):

Regeneron Pharmaceuticals, Inc.’s earning per share (EPS) fell -5.35% since last year same period to 9.55 in the Q1 2024. This indicates that the Regeneron Pharmaceuticals, Inc. has generated -5.35% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Regeneron Pharmaceuticals, Inc.’s return on assets (ROA) stands at 0.08.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Regeneron Pharmaceuticals, Inc.’s return on equity (ROE) stands at 0.15.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2024-05-02
10.09
9.55
-5.35%